Teachers Advisors LLC boosted its position in shares of Haemonetics Corporation (NYSE:HAE) by 5.1% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 89,362 shares of the medical instruments supplier’s stock after buying an additional 4,337 shares during the period. Teachers Advisors LLC’s holdings in Haemonetics Corporation were worth $3,625,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in the stock. Ameritas Investment Partners Inc. purchased a new stake in shares of Haemonetics Corporation during the first quarter worth about $179,000. State of Alaska Department of Revenue raised its stake in shares of Haemonetics Corporation by 2.3% in the first quarter. State of Alaska Department of Revenue now owns 5,740 shares of the medical instruments supplier’s stock worth $232,000 after buying an additional 130 shares in the last quarter. AXA purchased a new stake in shares of Haemonetics Corporation during the first quarter worth about $292,000. Kirr Marbach & Co. LLC IN raised its stake in shares of Haemonetics Corporation by 1.1% in the first quarter. Kirr Marbach & Co. LLC IN now owns 7,230 shares of the medical instruments supplier’s stock worth $293,000 after buying an additional 80 shares in the last quarter. Finally, Stevens Capital Management LP raised its stake in shares of Haemonetics Corporation by 61.9% in the first quarter. Stevens Capital Management LP now owns 8,830 shares of the medical instruments supplier’s stock worth $358,000 after buying an additional 3,375 shares in the last quarter.

Haemonetics Corporation (HAE) opened at 42.52 on Thursday. The firm’s 50-day moving average is $40.10 and its 200 day moving average is $40.13. Haemonetics Corporation has a 52 week low of $32.76 and a 52 week high of $43.74. The stock has a market cap of $2.24 billion, a price-to-earnings ratio of 552.21 and a beta of 0.90.

Haemonetics Corporation (NYSE:HAE) last posted its quarterly earnings results on Monday, August 7th. The medical instruments supplier reported $0.33 EPS for the quarter, beating the consensus estimate of $0.31 by $0.02. The company had revenue of $211 million during the quarter, compared to analysts’ expectations of $211.29 million. Haemonetics Corporation had a return on equity of 11.07% and a net margin of 0.48%. The firm’s revenue was up .5% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.25 EPS. On average, equities research analysts expect that Haemonetics Corporation will post $1.61 EPS for the current year.

WARNING: This report was reported by Watch List News and is the sole property of of Watch List News. If you are viewing this report on another domain, it was illegally copied and reposted in violation of US & international trademark & copyright legislation. The legal version of this report can be accessed at https://www.watchlistnews.com/teachers-advisors-llc-has-3-63-million-position-in-haemonetics-corporation-nysehae/1469211.html.

A number of brokerages recently issued reports on HAE. Zacks Investment Research raised shares of Haemonetics Corporation from a “hold” rating to a “buy” rating and set a $47.00 price objective for the company in a report on Wednesday. TheStreet raised shares of Haemonetics Corporation from a “c” rating to a “b-” rating in a report on Monday. BidaskClub raised shares of Haemonetics Corporation from a “strong sell” rating to a “sell” rating in a report on Tuesday. Barrington Research raised shares of Haemonetics Corporation from a “market perform” rating to an “outperform” rating and set a $48.00 price objective for the company in a report on Tuesday. Finally, Jefferies Group LLC reissued a “buy” rating and issued a $48.00 price objective on shares of Haemonetics Corporation in a report on Thursday, July 27th. Two analysts have rated the stock with a sell rating, four have issued a hold rating and four have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $40.63.

In other Haemonetics Corporation news, Director Ronald Merriman sold 17,471 shares of Haemonetics Corporation stock in a transaction dated Monday, May 22nd. The stock was sold at an average price of $40.33, for a total value of $704,605.43. Following the completion of the sale, the director now owns 24,925 shares in the company, valued at approximately $1,005,225.25. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 1.20% of the stock is owned by insiders.

About Haemonetics Corporation

Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company’s segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals.

Want to see what other hedge funds are holding HAE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Haemonetics Corporation (NYSE:HAE).

Institutional Ownership by Quarter for Haemonetics Corporation (NYSE:HAE)

Receive News & Ratings for Haemonetics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.